16 May 2016
Mumbai
Reporter: Tammy Facey

India grants Gilead Sciences patent for Sovaldi


Gilead Sciences has had its patent application for hepatitis C treatment Sovaldi (sofosbuvir) accepted in India.

The Indian Intellectual Property Office (IIPO) granted Gilead’s application for the patent on 7 May, after rejecting its initial application in January last year.

The IIPO initially rejected the application on the ground of evergreening, ruling that the mere discovery of a new form of a known substance, which does not result in the enhancement of the known efficacy of the substance, is not eligible for patent protection.

Gilead appealed against the decision and on 7 May the IIPO approved the formulation, describing the drug compound as novel and inventive.

Gilead faced opposition from the Initiative for Medicines, Access and Knowledge (I-MAK) over access to the drug in certain countries.

I-MAK claimed the treatment was too expensive. The recommended 12-week course of treatments costs $84,000 in the US, or $1,000 per pill.

But in India, Gilead is engaged in voluntary licensing programmes with 11 generic manufacturers.

As of 26 April, the cost of Sovaldi was $384 per bottle, or around $14 per pill, in India, according to the Asia Pacific Network of People Living with HIV.

A spokesperson for Gilead commented: “We welcome news that the [IIPO] of New Delhi has granted our patent application.”

The spokesperson added: “[Our current] licensing programme enables the manufacture and distribution of high-quality, low-cost versions of the company’s medicines for HIV, hepatitis B and hepatitis C.”

More Asia news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
Trump fires forward in China IP investigation
15 August 2017 | Washington DC | Reporter: Barney Dixon
US President Donald Trump has signed a memorandum asking the US Trade Representative to examine whether China should be investigated for alleged intellectual property malpractice
SIPO launches new IP rights centre
03 August 2017 | Shanghai | Reporter: Barney Dixon
The centre will focus on providing fast protection for rights in the manufacturing and biopharmaceutical industries
China streamlines patent filing
02 August 2017 | Beijing | Reporter: Barney Dixon
The rules, which went into effect on 1 August, will reduce filing burdens and improve the efficiency of administrative services in specific fields
New Zealand joins GPPH
24 July 2017 | Wellington | Reporter: Barney Dixon
New Zealand is the latest member of the Global Patent Prosecution Highway, joining 17 other countries participating in the agreement
Spruson & Ferguson launches Melbourne trademark office
12 June 2017 | Melbourne | Reporter: Barney Dixon
Law firm Spruson & Ferguson has opened a boutique trademark office in Melbourne, Australia
IP Group invests in Australian innovation
07 June 2017 | Canberra | Reporter: Barney Dixon
UK-based intellectual property investment company IP Group has committed AUD 200 million (USD 151.1 million) to Australia’s Group of Eight coalition
China could establish appellate IP court
15 May 2017 | Chengdu | Reporter: Barney Dixon
The court would be modelled on the US Court of Appeals for the Federal Circuit and cover mainly technology-related issues